Generation Bio - GBIO Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GBIO shares.
View GBIO analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month price targets for Generation Bio's stock. Their GBIO share price forecasts range from $2.23 to $24.00. On average, they anticipate the company's stock price to reach $12.31 in the next twelve months. This suggests a possible upside of 217.2% from the stock's current price.
View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts.

Generation Bio's stock was trading at $3.93 at the beginning of the year. Since then, GBIO shares have decreased by 1.3% and is now trading at $3.88.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our GBIO earnings forecast.

Generation Bio Co. (NASDAQ:GBIO) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.02.

Fidelity Blue Chip Growth ETF holds 849 shares of GBIO stock, representing 0.00% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

(GBIO) raised $126 million in an IPO on Friday, June 12th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."

Generation Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (12.22%), T. Rowe Price Investment Management Inc. (6.02%), Geode Capital Management LLC (1.46%), Bank of America Corp DE (1.46%), Morgan Stanley (0.83%) and JPMorgan Chase & Co. (0.78%). Insiders that own company stock include Antoinette Paone, Charles A Rowland Jr, Donald William Nicholson, Douglas Kerr, Evan Spiegel, Geoff Mcdonough, James E Flynn, Jason P Rhodes, Matthew Stanton, Phillip Samayoa and Venture Associates X L Atlas.
View institutional ownership trends.

Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GBIO stock can currently be purchased for approximately $3.88.

Generation Bio (NASDAQ:GBIO) has a market capitalization of $231.52 million. The company earns $-136,640,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

The company employs 150 workers across the globe.

Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is generationbio.com. The company can be reached via phone at 617-655-7500 or via email at investors@generationbio.com.